Egyptian International Pharmaceutical Industries Company Stock
Equities
PHAR
EGS38081C013
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 79.99 EGP | +1.38% |
|
+3.07% | +3.21% |
| 12-11 | Eipico says Eipico 3 facility gets final operating license from Egyptian Drug Authority | RE |
| 11-16 | Eipico 9-month consol profit egp 1.09 billion | RE |
| Capitalization | 13.5B 285M 244M 226M 212M 394M 26.12B 422M 2.6B 1.03B 12.35B 1.07B 1.05B 45.1B | P/E ratio 2025 * |
8.08x | P/E ratio 2026 * | 7.22x |
|---|---|---|---|---|---|
| Enterprise value | 20.14B 425M 364M 338M 317M 588M 38.97B 629M 3.88B 1.53B 18.42B 1.6B 1.56B 67.28B | EV / Sales 2025 * |
2.1x | EV / Sales 2026 * | 1.73x |
| Free-Float |
45.72% | Yield 2025 * |
3.75% | Yield 2026 * | 5.38% |
| 1 day | +1.38% | ||
| 1 week | +3.07% | ||
| Current month | +3.21% | ||
| 1 month | +11.04% | ||
| 3 months | +1.25% | ||
| 6 months | +52.10% | ||
| Current year | +3.21% |
| 1 week | 75.91 |  | 79.99 |
| 1 month | 67.5 | | 82 |
| Current year | 75.45 | | 82 |
| 1 year | 43.51 | | 83.99 |
| 3 years | 24.5 | | 83.99 |
| 5 years | 24.5 | | 83.99 |
| 10 years | 24.5 | | 122.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | - | |
| Investor Relations Contact | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | - | |
| Director/Board Member | - | - | |
| Chairman | - | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.38% | +3.07% | +67.76% | +100.78% | 285M | |
| +0.27% | -4.75% | -8.10% | +54.39% | 42.25B | |
| +1.89% | -0.34% | +13.86% | +119.14% | 29.92B | |
| +0.46% | -3.91% | -3.47% | +29.73% | 12.08B | |
| +0.94% | +0.10% | -10.27% | +99.10% | 9.63B | |
| -0.25% | -5.94% | +66.02% | +39.00% | 8.24B | |
| +0.92% | +0.46% | +43.79% | +127.27% | 7.84B | |
| -.--% | +0.14% | - | - | 6.79B | |
| +0.91% | -0.90% | +40.23% | -22.01% | 6.67B | |
| +1.95% | -1.49% | +32.14% | +373.23% | 5.98B | |
| Average | +0.89% | -1.52% | +26.88% | +102.29% | 12.97B | |
| Weighted average by Cap. | +0.89% | -3.04% | +10.57% | +86.33% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 9.58B 202M 173M 161M 151M 279M 18.53B 299M 1.84B 729M 8.76B 759M 743M 31.99B | 11.49B 243M 208M 193M 181M 335M 22.24B 359M 2.21B 875M 10.51B 910M 892M 38.39B |
| Net income | 1.52B 32.08M 27.43M 25.46M 23.88M 44.3M 2.94B 47.44M 292M 116M 1.39B 120M 118M 5.07B | 1.75B 36.89M 31.54M 29.28M 27.46M 50.94M 3.38B 54.55M 336M 133M 1.6B 138M 136M 5.83B |
| Net Debt | 6.64B 140M 120M 111M 104M 194M 12.85B 207M 1.28B 506M 6.07B 526M 515M 22.18B | 6.39B 135M 116M 107M 101M 187M 12.37B 200M 1.23B 487M 5.85B 507M 496M 21.36B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 21/01/26 | 79.99 £ | +1.38% | 126,054 |
| 20/01/26 | 78.90 £ | +0.01% | 347,040 |
| 19/01/26 | 78.89 £ | +2.20% | 415,136 |
| 18/01/26 | 77.19 £ | +1.07% | 28,831 |
| 15/01/26 | 76.37 £ | -0.92% | 80,933 |
End-of-day quote Egyptian Exchange, January 21, 2026
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- PHAR Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition